A Prospective, Randomized, Placebo-Controlled Double Blind, 18 Month Study Evaluating the Efficacy and Tolerability of Lithium Orotate 10 mg Daily in Patients With Alzheimer's Disease and Mild Cognitive Impairment. (LIORA)
Efficacy and Tolerability of Lithium Orotate in Alzheimer's Disease and Mild Cognitive Impairment
This is a prospective, multi-center, randomized, placebo-controlled, double-blind clinical trial lasting 18 months. Participants will be randomized to 1:1 to Lithium Orotate or matching placebo. Double-blinding will be maintained for investigators, participants, and outcome assessors. An independent data monitoring committee will oversee safety. The study will utilize Lithium Orotate 5 mg twice daily. The U.S. Manufacturer is Nitricost. It is a synthetic, stable Lithium Salt. The Nutricost 5 mg capsules only contain Lithium Orotate. There is no Lithium Carbonate in the 5 mg product. The Lithium Carbonate is undesirable because it is sequestered in Amyloid Plaques. The Lithium Orotate has been shown to be resist degradation and sequestration by the Amyloid Plaques.
Recruitment is 6 months.
Treatment phase is 18 months. Follow up is 1 month for post treatment for safety.
Inclusion Criteria is adults aged 50-90 years; Diagnosis of probable Alzheimer's Disease (per NIA-AA criteria) or MCI (per Peterson criteria). Baseline MMSE score of 18-26 (for AD) or 24-30 (for MCI). Participants must be stable on approved AD medications (if applicable) for >3 months. Participants must provide informed consent (or via legally authorized representative).
Exclusion Criteria includes: Severe renal impairment of eGFR <40, or CKD III-IV, History of Bipolar disorder or other lithium contraindications, Concomitant use of medications interacting with Lithium (e.g., diuretics, NSAIDs), Significant comorbidities (e.g., uncontrolled hypertension, recent stroke), Pregnancy or breastfeeding,
The Risk Benefit Ratio is extremely low. 1/100. The relative risk of using Lithium Orotate is extremely small compared to the possible significant benefits. The FDA has cleared the use of Lithium Orotate in this clinical trial.
The Sample Size is 200 participants (100 per arm), powered to detect a 2-point difference in MMSE change (SD=4, a+-=0.05, power=80%, 20% attrition). Stratification by AD/MCI status and age.
The Active Arm is Lithium Orotate capsules 10 mg orally daily. The Placebo Arm is Identical placebo capsules daily. Dosing of Lithium Orotate will be titrated down to 5 mg QD, if needed for tolerability. Compliance will be assessed via pill counts and patient diaries.
The Primary Endpoint is change in MMSE score from baseline, assessed every 3 months. Secondary Endpoint is PET Scan changes of Amyloid burden and/or Tau pathology at baseline and 18 months. PET Scans are optional only for participants that have an allergy to the PET Scan radionuclide, or have significant difficulty in transfers or transports to the imaging facility. Some participants will likely be home bound and unable to comply.
Safety and Incidence of adverse events (AEs), serious AEs and discontinuations will be monitored via common terminology criteria for adverse events (CTCAE).
Tolerability will be monitored via vital signs, renal functions (eGFR), thyroid function (TSH) and electrolyte panels every 3 months.
調査の概要
状態
条件
詳細な説明
Every 3 months Participants will have MMSE, Safety labs, AE reporting. At each 3 month visit an assessment for side effects and safety will be noted in the body of the progress note under Objective. Every 3 months an MMSE will also be performed and compared with the last MMSE. If there is a 2 point change in MMSE, the study will be unblinded for those participants. These participants will be given the option to continue with the Lithium Orotate or change from Placebo to Lithium Orotate.
The Endpoint (18 months) will include MMSE, PET Scan all assessments.
Data Monitoring will include MMSE results (0 to 30) and Clock Drawing Test results (Pass or Fail) will be scanned into the Practice Fusion EMR. Nobody has access to the HIPPA protected information but myself and my staff. All participants will sign a HIPPA form. Practice Fusion is a Cloud-Based EMR that has an excellent reputation for secure privacy of patient information. The laboratory blood tests will be from Quest Laboratory which interfaces with Practice Fusion. If there is a significant drop in GFR or Hemoglobin, or an abnormal rise in Liver Function Tests, the trial will be suspended in those participants, and they will be referred back to their primary care doctor. Laboratory results will be discussed with the participant and HCS/POA during office visits every 3 months. The PET Scan results will be faxed to my office from Simon Med Imaging to my office and scanned into the EMR after they are discussed with the participant and HCS/POA, if present.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:ROBERT B KOSER, MD
- 電話番号:941-795-1135
- メール:bluesinjector@yahoo.com
研究連絡先のバックアップ
- 名前:ROBERT B KOSER, MD
- 電話番号:941-348-0303
- メール:bluesinjector54@gmail.com
研究場所
-
-
Florida
-
Bradenton、Florida、アメリカ、34209
- Robert B Koser Md
-
コンタクト:
- ROBERT B KOSER, MD
- 電話番号:941-795-1135
- メール:bluesinjector@yahoo.com
-
コンタクト:
- ROBERT B KOSER, MD
- 電話番号:941-348-0303
- メール:bluesinjector54@gmail.com
-
主任研究者:
- ROBERT B KOSER, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Participants having Alzheimer's Disease or Mild Cognitive Impairment
説明
Inclusion Criteria: Diagnosis of probable Alzheimer's Disease (per NIA-AA criteria) or Mild Cognitive Impairment (per Petersen criteria). Baseline MMSE score of 18-26 for AD or 24-30 for MCI. Stable on approved AD medications (if applicable) for >3 months. Ability to provide informed consent (or via legally authorized representative.
-
Exclusion Criteria: Severe renal impairment: eGFR <40 mL/min, or CKD III-V. History of Bipolar disorder or other lithium contraindications (e.g., Hypothyroidism). Concomitant use of medications interacting with lithium (e.g., diuretics, NSAIDs). Significant comorbidities (e.g., uncontrolled Hypertension, recent Stroke). Pregnancy or breastfeeding.
-
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_CROSSOVER
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Placebo
Placebo |
|
Lithium Orotate 10 mg
Lithium Orotate will be given to half the participants to see if it prevents or reverses cognitive decline in MCI or Alzheimer's patients. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
2 Point change in MMSE Scores. Clock Drawing Tests change pass to fail or vice versa.
時間枠:18 months
|
Every 3 months |
18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Amyloid changes on PET Scans with Centiloid Scores.
時間枠:18 months
|
Initial PET at onset of study and at end of study |
18 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:ROBERT B KOSER, MD、ROBERT B KOSER MD PA
出版物と役立つリンク
一般刊行物
- Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res. 2013 Jan;10(1):104-7. doi: 10.2174/1567205011310010014.
- Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. Br J Psychiatry. 2019 Nov;215(5):668-674. doi: 10.1192/bjp.2019.76.
- Lu Q, Lv H, Liu X, Zang L, Zhang Y, Meng Q. Lithium Therapy's Potential to Lower Dementia Risk and the Prevalence of Alzheimer's Disease: A Meta-Analysis. Eur Neurol. 2024;87(2):93-104. doi: 10.1159/000538846. Epub 2024 Apr 24.
- Kessing LV, Gerds TA, Knudsen NN, Jorgensen LF, Kristiansen SM, Voutchkova D, Ernstsen V, Schullehner J, Hansen B, Andersen PK, Ersboll AK. Association of Lithium in Drinking Water With the Incidence of Dementia. JAMA Psychiatry. 2017 Oct 1;74(10):1005-1010. doi: 10.1001/jamapsychiatry.2017.2362.
- Aron L, Ngian ZK, Qiu C, Choi J, Liang M, Drake DM, Hamplova SE, Lacey EK, Roche P, Yuan M, Hazaveh SS, Lee EA, Bennett DA, Yankner BA. Lithium deficiency and the onset of Alzheimer's disease. Nature. 2025 Sep;645(8081):712-721. doi: 10.1038/s41586-025-09335-x. Epub 2025 Aug 6.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Journal of Nature. Neurology Reviews. American Family Physician. Journal of Family Practice.
IPD 共有時間枠
Spring 2028
IPD 共有アクセス基準
Website to be determined
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。